<span item_type="fundamental" item_id="70122eea05f90fcf08297f430ee70161" counter_id="ST/US/NXGLW" env="prod"></span><span item_type="announcement" item_id="548731232210259457" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 2.884 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.09.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -640 K.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>NexGel Segment</strong>: Revenue for the three months ended June 30, 2025, was $2,333 thousand, compared to $1,090 thousand for the same period in 2024. For the six months ended June 30, 2025, revenue was $4,331 thousand, compared to $1,941 thousand in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468929/000164117225023236/form10-q.htm"></span></li><li><strong>CGN JV Segment</strong>: Revenue for the three months ended June 30, 2025, was $551 thousand, compared to $350 thousand for the same period in 2024. For the six months ended June 30, 2025, revenue was $1,359 thousand, compared to $765 thousand in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468929/000164117225023236/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>NexGel Segment</strong>: Loss from operations for the three months ended June 30, 2025, was - $711 thousand, compared to - $937 thousand for the same period in 2024. For the six months ended June 30, 2025, the loss was - $1,583 thousand, compared to - $1,716 thousand in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468929/000164117225023236/form10-q.htm"></span></li><li><strong>CGN JV Segment</strong>: Income from operations for the three months ended June 30, 2025, was $75 thousand, compared to a loss of - $117 thousand for the same period in 2024. For the six months ended June 30, 2025, income was $170 thousand, compared to a loss of - $209 thousand in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468929/000164117225023236/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities for the six months ended June 30, 2025, was - $807 thousand, compared to - $1,792 thousand for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468929/000164117225023236/form10-q.htm"></span></li><li><strong>Free Cash Flow</strong>: Not explicitly stated, but net cash used in investing activities was - $20 thousand for the six months ended June 30, 2025, compared to - $704 thousand in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468929/000164117225023236/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Branded Consumer Products</strong>: Revenue for the three months ended June 30, 2025, was $1,884 thousand, compared to $968 thousand for the same period in 2024. For the six months ended June 30, 2025, revenue was $3,666 thousand, compared to $1,585 thousand in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468929/000164117225023236/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to maintain and grow its existing contract manufacturing business and continue developing its catalogue of consumer products for sale to branding partners. It also aims to develop proprietary medical devices and explore drug delivery programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468929/000164117225023236/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring new product channel sales in adjacent industries such as cosmetics and athletic products, and continues to evaluate strategic initiatives, including acquisitions and additional capital raises through debt or equity.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1468929/000164117225023236/form10-q.htm"></span></li></ul>

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 2.884 M